ANI Pharmaceuticals Inc (ANIP) Position Boosted by Chicago Equity Partners LLC

Chicago Equity Partners LLC increased its position in shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 3.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 39,558 shares of the specialty pharmaceutical company’s stock after buying an additional 1,483 shares during the period. Chicago Equity Partners LLC owned 0.33% of ANI Pharmaceuticals worth $2,237,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Piedmont Investment Advisors LLC acquired a new position in ANI Pharmaceuticals during the second quarter worth $140,000. Truvestments Capital LLC acquired a new position in ANI Pharmaceuticals during the third quarter worth $152,000. Crossmark Global Holdings Inc. acquired a new position in ANI Pharmaceuticals during the second quarter worth $235,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp acquired a new position in ANI Pharmaceuticals during the second quarter worth $267,000. Finally, Campbell & CO Investment Adviser LLC acquired a new position in ANI Pharmaceuticals during the second quarter worth $272,000. Institutional investors and hedge funds own 61.10% of the company’s stock.

A number of equities analysts recently weighed in on ANIP shares. BidaskClub downgraded shares of ANI Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Wednesday, September 19th. Cantor Fitzgerald set a $74.00 target price on shares of ANI Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, October 3rd. ValuEngine upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 23rd. Finally, Canaccord Genuity set a $75.00 target price on shares of ANI Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 16th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $71.00.

NASDAQ:ANIP opened at $52.66 on Friday. ANI Pharmaceuticals Inc has a one year low of $48.40 and a one year high of $74.70. The firm has a market capitalization of $639.13 million, a price-to-earnings ratio of 12.25 and a beta of 2.64. The company has a debt-to-equity ratio of 1.04, a quick ratio of 2.89 and a current ratio of 3.34.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Tuesday, November 6th. The specialty pharmaceutical company reported $1.29 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.17 by $0.12. ANI Pharmaceuticals had a net margin of 0.23% and a return on equity of 28.39%. The firm had revenue of $50.70 million for the quarter, compared to the consensus estimate of $50.97 million. During the same period in the previous year, the company earned $1.11 earnings per share. The company’s quarterly revenue was up 5.3% on a year-over-year basis. On average, analysts predict that ANI Pharmaceuticals Inc will post 4.49 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://www.dispatchtribunal.com/2018/11/11/ani-pharmaceuticals-inc-anip-position-boosted-by-chicago-equity-partners-llc.html.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis.

Featured Article: What factors cause inflation to rise?

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals Inc (NASDAQ:ANIP).

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply